<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886119</url>
  </required_header>
  <id_info>
    <org_study_id>P-319-C-005 sub 8</org_study_id>
    <nct_id>NCT00886119</nct_id>
  </id_info>
  <brief_title>Comparison of a Multifocal Contact Lens to a Traditional Multifocal Contact Lens</brief_title>
  <official_title>Lotrafilcon B Multifocal Evaluations - Comparison to a Traditional Multifocal in Higher Spectacle Adds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIBA VISION</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <brief_summary>
    <textblock>
      The purpose of the trial is to compare the performance of two multifocal contact lens
      systems/products in established presbyopic subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Corrected Distance Binocular Visual Measurement in Normal Illumination Reported as Binocular Distance Visual Acuity</measure>
    <time_frame>After 1 week of wear</time_frame>
    <description>Tested while reading charts distant to the subject with both eyes together in normal lighting. This outcome is measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 equates to 20/20 Snellen acuity and is considered normal. Positive logMAR values indicate poorer vision and negative values denote better visual acuity.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Lotrafilcon B / Omafilcon A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Lotrafilcon B, followed by Omafilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Omafilcon A / Lotrafilcon B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Omafilcon A, followed by Lotrafilcon B</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon B multifocal contact lens</intervention_name>
    <description>Silicone hydrogel, soft, multifocal contact lens for daily wear use</description>
    <arm_group_label>Lotrafilcon B / Omafilcon A</arm_group_label>
    <arm_group_label>Omafilcon A / Lotrafilcon B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Omafilcon A multifocal contact lens</intervention_name>
    <description>Hydrogel, soft, multifocal contact lens for daily wear use</description>
    <arm_group_label>Lotrafilcon B / Omafilcon A</arm_group_label>
    <arm_group_label>Omafilcon A / Lotrafilcon B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 35 years of age.

          -  Best-corrected visual acuity of at least 20/40 in each eye.

          -  Spectacle add from +1.50D and +2.50D (inclusive).

          -  Able to be fit in available study sphere powers (Plano to -4.00D).

          -  Currently wearing soft contact lenses at least 5 days a week.

          -  Other protocol inclusion / exclusion criteria may apply.

        Exclusion Criteria:

          -  Requires concurrent ocular medication.

          -  Eye injury or surgery within twelve weeks immediately prior to enrollment.

          -  Currently enrolled in an ophthalmic clinical trial.

          -  Evidence of systemic or ocular abnormality, infection or disease likely to affect
             successful wear of contact lenses or use of their accessory solutions.

          -  Previous refractive surgery.

          -  Astigmatism &gt; 1.00D.

          -  Currently wearing Proclear Multifocal, Frequency 55 Multifocal or Biomedics EP contact
             lenses.

          -  Other protocol inclusion / exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2009</study_first_submitted>
  <study_first_submitted_qc>April 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2009</study_first_posted>
  <results_first_submitted>September 14, 2010</results_first_submitted>
  <results_first_submitted_qc>October 6, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 29, 2010</results_first_posted>
  <last_update_submitted>June 26, 2012</last_update_submitted>
  <last_update_submitted_qc>June 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two participants were enrolled but not dispensed due to failing inclusion/exclusion criteria. These participants were included in the Actual Enrollment calculation, but not Participant Flow or Baseline Characteristics calculations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lotrafilcon B / Omafilcon A</title>
          <description>Lotrafilcon B multifocal contact lens worn first, with Omafilcon A multifocal contact lens worn second. Both products worn in a daily wear basis.</description>
        </group>
        <group group_id="P2">
          <title>Omafilcon A / Lotrafilcon B</title>
          <description>Omafilcon A multifocal contact lens worn first, with Lotrafilcon B multifocal contact lens worn second. Both products worn in a daily wear basis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not meet inclusion criteria</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall</title>
          <description>This reporting group includes all enrolled and dispensed subjects.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.3" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Corrected Distance Binocular Visual Measurement in Normal Illumination Reported as Binocular Distance Visual Acuity</title>
        <description>Tested while reading charts distant to the subject with both eyes together in normal lighting. This outcome is measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 equates to 20/20 Snellen acuity and is considered normal. Positive logMAR values indicate poorer vision and negative values denote better visual acuity.</description>
        <time_frame>After 1 week of wear</time_frame>
        <population>Per Protocol. Analysis excluded major protocol deviations as determined by masked review.</population>
        <group_list>
          <group group_id="O1">
            <title>Lotrafilcon B</title>
            <description>Silicone hydrogel, soft, multifocal contact lens for daily wear use</description>
          </group>
          <group group_id="O2">
            <title>Omafilcon A</title>
            <description>Hydrogel, soft, multifocal contact lens for daily wear</description>
          </group>
        </group_list>
        <measure>
          <title>Corrected Distance Binocular Visual Measurement in Normal Illumination Reported as Binocular Distance Visual Acuity</title>
          <description>Tested while reading charts distant to the subject with both eyes together in normal lighting. This outcome is measured in logMAR units (logarithm of the minimum angle of resolution). A logMAR acuity of 0.0 equates to 20/20 Snellen acuity and is considered normal. Positive logMAR values indicate poorer vision and negative values denote better visual acuity.</description>
          <population>Per Protocol. Analysis excluded major protocol deviations as determined by masked review.</population>
          <units>logMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.07"/>
                    <measurement group_id="O2" value="-0.02" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 weeks, the duration of the trial.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lotrafilcon B</title>
          <description>Silicone hydrogel, soft, multifocal contact lens for daily wear</description>
        </group>
        <group group_id="E2">
          <title>Omafilcon A</title>
          <description>Hydrogel, soft, multifocal contact lens for daily wear</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="46"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any pre-clinical and/or clinical data or impressions from this trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Priya Janakiraman, OD, FAAO / Head, Global Clinical Affairs</name_or_title>
      <organization>CIBA VISION</organization>
      <phone>1-800-241-7629</phone>
      <email>priya.janakiraman@cibavision.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

